Uncategorized
ThromboGenics receives FDA approval for new formulation of Jetrea
The Office of Biotechnology Products of the FDA has approved an already diluted formulation of Jetrea, according to a press release from ThromboGenics. The new Jetrea (ocriplasmin) formulation eliminates “the current preparatory dilution steps prior to injection.” According to the release, when Jetrea is administered to the eye, the strength, potency, composition and pharmaceutical form of the new formulation will remain identical to the currently available formulation of Jetrea after dilution.